α-1-Antitrypsin deficiency: Clinical variability, assessment, and treatment

Trends in Molecular Medicine

Volumn 20, Issue 2, 2014, Pages 105-115

  Stockley, Robert A ^a   Turner, Alice M ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

1 antitrypsin deficiency; Biomarkers; Gene therapy

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CHEMOATTRACTANT; ELASTIN; GAMMA GLUTAMYLTRANSFERASE;

ADENO ASSOCIATED VIRUS; ALPHA 1 ANTITRYPSIN DEFICIENCY; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; DNA METHYLATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; FORCED EXPIRATORY VOLUME; GAS DIFFUSION; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; HEMATOPOIETIC STEM CELL; HOMOZYGOSITY; HUMAN; LUNG EMPHYSEMA; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUTROPHIL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLURIPOTENT STEM CELL; POINT MUTATION; QUANTITATIVE TRAIT LOCUS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL GENE THERAPY; COMORBIDITY; DNA MODIFICATION; GENE THERAPY; LUNG DISEASE; STEM CELL; STEM CELL TRANSPLANTATION;

BIOMARKERS; GENE THERAPY; Α-1-ANTITRYPSIN DEFICIENCY;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANIMALS; BIOLOGICAL MARKERS; ENZYME REPLACEMENT THERAPY; EPIGENESIS, GENETIC; GENETIC THERAPY; HUMANS; STEM CELL TRANSPLANTATION;

EID: 84893679825     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.11.006     Document Type: Review

References (121)

1. Laurell C., Eriksson S. The electrophorectic α1-globulin pattern of serum in α1-antitrypsin deficiency. Scand. J. Clin. Lab. Invest. 1963, 15:132-140.
2. Senior R.M., et al. The induction of pulmonary emphysema with human leukocyte elastase. Am. Rev. Respir. Dis. 1977, 116:469-475.
3. Brantly M.L., et al. Molecular basis of α-1 antitrypsin deficiency. Am. J. Med. 1988, 84:13-31.
4. Ogushi F., et al. Z-type α1-antitrypsin is less competent than M1-type α-1-antitrypsin as an inhibitor of neutrophil elastase. J. Clin. Invest. 1987, 80:1366-1374.
5. Lomas D.A., et al. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992, 357:605-607.
6. Kao R.C., et al. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J. Clin. Invest. 1988, 82:1963-1973.
7. Lucey E.C., et al. Effect of combined human neutrophil cathepsin G and elastase on induction of secretory cell metaplasia and emphysema in hamsters, with in vitro observations on elastolysis by these enzymes. Am. Rev. Respir. Dis. 1985, 132:362-366.
8. Lesser M., et al. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am. Rev. Respir. Dis. 1992, 145:661-668.
9. Jonigk D., et al. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:15007-15012.
10. Churg A., et al. α1-Antitrypsin suppresses TNF-α and MMP-12 production by cigarette smoke-stimulated macrophages. Am. J. Respir. Cell Mol. Biol. 2007, 37:144-151.
11. Eriksson S. Studies in α1-antitrypsin deficiency. Acta Med. Scand. Suppl. 1965, 432:1-85.
12. Wood A.M., et al. Phenotypic differences in α1 antitrypsin deficient sibling pairs may relate to genetic variation. COPD 2008, 5:353-359.
13. Parr D.G., et al. Pattern of emphysema distribution in α-1-antitrypsin deficiency influences lung function impairment. Am. J. Respir. Crit. Care Med. 2004, 170:1172-1178.
14. Holme J., Stockley R.A. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from α-1-antitrypsin deficiency. Chest 2007, 132:909-915.
15. Holme J., et al. Age related development of respiratory abnormalities in non-index α1 antitrypsin deficient studies. Respir. Med. 2013, 107:387-393.
16. Bernspang E., et al. Lung function in 30-year-old α-1-antitrypsin-deficient individuals. Respir. Med. 2009, 103:861-865.
17. 1-antitrypsin deficiency. Pulmonary Emphysema and Proteolysis 1972, 69-89. Academic Press. C. Mittman (Ed.).
18. Parr D.G., et al. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study augmentation therapy in α-1-antitrypsin deficiency. Respir. Res. 2009, 10:75.
19. World Health Organisation Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull. World Health Organ. 1997, 75:397-415.
20. Shin M.S., Ho K.J. Bronchiectasis in patients with α1-antitrypsin deficiency. A rare occurrence?. Chest 1993, 104:1384-1386.
21. Parr D.G., et al. Prevalence and impact of bronchiectasis in α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2007, 176:1215-1221.
22. O'Brien C., et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000, 55:635-642.
23. Cuvelier A., et al. Distribution of α(1)-antitrypsin alleles in patients with bronchiectasis. Chest 2000, 117:415-419.
24. Dowson L.J., et al. Longitudinal changes in physiological, radiological and health status measurements in α1-antitrypsin deficiency and factors associated with decline. Am. J. Respir. Crit. Care Med. 2001, 164:1805-1809.
25. Dawkins P.A., et al. Rate of progression of lung function impairment in α-1-antitrypsin deficiency. Eur. Respir. J. 2009, 33:1338-1344.
26. Dowson L.J., et al. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in α1-antitrypsin deficiency (PiZ). Chest 2002, 122:1247-1255.
27. Gompertz S., et al. Effect of expectoration on inflammation in induced sputum in α-1-antitrypsin deficiency. Respir. Med. 2006, 100:1094-1099.
28. Hill A.T., et al. Evidence for excessive bronchial inflammation during an acute exacerbation of COPD in patients with α-1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 1999, 160:1968-1975.
29. Sinden N.J., Stockley R.A. Proteinase 3 activity in sputum from subjects with α-1-antitrypsin deficiency and COPD. Eur. Respir. J. 2013, 41:1042-1050.
30. Needham M., Stockley R.A. Exacerbations in α-1-antitrypsin deficiency. Eur. Respir. J. 2005, 25:992-1000.
31. Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008, 133:34-41.
32. Vijayasaratha K., Stockley R.A. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in α-1 antitrypsin-deficient COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2012, 7:789-796.
33. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000, 118:1480-1485.
34. Dirksen A., et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency. Eur. Respir. J. 2009, 33:1345-1353.
35. Stockley R.A., et al. The effect of augmentation therapy on bronchial inflammation in α1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2002, 165:1494-1498.
36. Sveger T., Eriksson S. The liver in adolescents with α1-antitrypsin deficiency. Hepatology 1995, 22:514-517.
37. Sveger T. The natural history of liver disease in α1-antitrypsin deficient children. Acta Paediatr. Scand. 1988, 77:847-851.
38. Clark V.C., et al. Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. Clin. Gastroenterol. Hepatol. 2012, 10:1278-1283.
39. Dawwas M.F., et al. Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease. Am. J. Respir. Crit. Care Med. 2013, 187:502-508.
40. Teckman J.H. Liver disease in α-1 antitrypsin deficiency: current understanding and future therapy. COPD 2013, 10(Suppl. 1):35-43.
41. Smith K.C., et al. Panniculitis associated with severe α1-antitrypsin deficiency. Treatment and review of the literature. Arch. Dermatol. 1987, 123:1655-1661.
42. Borgmann S., et al. A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis. Clin. Immunol. 2001, 98:244-248.
43. Elzouki A.N., et al. The prevalence and clinical significance of α1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm. Bowel Dis. 1999, 5:246-252.
44. Qiu W., et al. Variable DNA methylation is associated with COPD and lung function. Am. J. Respir. Crit. Care Med. 2012, 185:373-381.
45. Sorheim I.C., et al. α(1)-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010, 138:1125-1132.
46. Obeidat M., et al. A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample. PLoS ONE 2011, 6:e19382.
47. Wood A.M., et al. Outdoor air pollution is associated with disease severity in α1-antitrypsin deficiency. Eur. Respir. J. 2009, 34:346-353.
48. Wood A.M., et al. Outdoor air pollution is associated with rapid decline of lung function in α-1-antitrypsin deficiency. Occup. Environ. Med. 2010, 67:556-561.
49. Hunninghake G.M., et al. MMP12, lung function, and COPD in high-risk populations. N. Engl. J. Med. 2009, 361:2599-2608.
50. McAloon C.J., et al. Matrix metalloprotease polymorphisms are associated with gas transfer in α 1 antitrypsin deficiency. Ther. Adv. Respir. Dis. 2009, 3:23-30.
51. DeMeo D., et al. Integration of genetic and genomic techniques identifies IREB2 as a COPD susceptibility gene. Am. J. Hum. Genet. 2009, 85:493-502.
52. Kim W.J., et al. Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe α-1 antitrypsin deficiency. Respir. Res. 2012, 13:16.
53. Wood A.M., et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011, 66:205-210.
54. Wood A.M., et al. The TNFα gene relates to clinical phenotype in α-1-antitrypsin deficiency. Respir. Res. 2008, 9:52.
55. Smolonska J., et al. Meta-analyses on suspected COPD genes - a summary of 20 years' research. Am. J. Respir. Crit. Care Med. 2009, 180:618-631.
56. Nicolae D.L., et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010, 6:e1000888.
57. Katsanis S.H., Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet. 2013, 14:415-426.
58. Tilley A.E., et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS ONE 2011, 6:e22798.
59. Shaykhiev R., et al. Smoking dependent reprogramming of alveolar macrophage activation: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 2009, 183:2867-2883.
60. Zhai Y., et al. Coordinated changes in mRNA turnover, translation, and RNA processing bodies in bronchial epithelial cells following inflammatory stimulation. Mol. Cell. Biol. 2008, 28:7414-7426.
61. Ezzie M.E., et al. Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 2012, 67:122-131.
62. Hubbard R.C., et al. Biochemical efficacy and safety of monthly augmentation therapy for α 1-antitrypsin deficiency. JAMA 1988, 260:1259-1264.
63. Dahl M., et al. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur. Respir. J. 2005, 26:67-76.
64. Liou T.G., Campbell E.J. Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. J. Immunol. 1996, 157:2624-2631.
65. Wewers M.D., et al. Replacement therapy for α1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 1987, 316:1055-1062.
66. Schluchter M.D., et al. Feasibility of a clinical trial of augmentation therapy for α(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am. J. Respir. Crit. Care Med. 2000, 161:796-801.
67. Seersholm N., et al. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary α1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) α1-AT Study Group. Eur. Respir. J. 1997, 10:2260-2263.
68. Wencker M., et al. Longitudinal follow-up of patients with α(1)-protease inhibitor deficiency before and during therapy with IV α(1)-protease inhibitor. Chest 2001, 119:737-744.
69. Chapman K.R., et al. Augmentation therapy for α1 antitrypsin deficiency: a meta-analysis. COPD 2009, 6:177-184.
70. 1 decline in individuals with severe deficiency of α1-antitrypsin. Am. J. Respir. Crit. Care Med. 1998, 158:49-59.
71. Parr D.G., et al. Validation of computed tomographic lung densitometry for monitoring emphysema in α-1-antitrypsin deficiency. Thorax 2006, 61:485-490.
72. Stolk J., et al. Retinoid treatment of emphysema in patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. Ther. Adv. Respir. Dis. 2010, 4:319-332.
73. Dirksen A., et al. A randomized clinical trial of α(1)-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 1999, 160:1468-1472.
74. Parr D.G., et al. Detection of emphysema progression in α1-antitrypsin deficiency using CT densitometry; methodological advances. Respir. Res. 2008, 13:21.
75. Hubbard R.C., et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in α 1-antitrypsin deficiency directly augmented with an aerosol of α 1-antitrypsin. Ann. Intern. Med. 1989, 111:206-212.
76. Stockley R.A. Long-term intervention studies: α1-antitrypsin substitution. Long-term Intervention in Chronic Obstructive Pulmonary Disease 2005, 445-462. Marcel Dekker. R.A. Pauwels (Ed.).
77. Woolhouse I.S., et al. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of α1-antitrypsin deficiency and the role of leukotriene B4 and interleukin 8. Thorax 2002, 57:709-714.
78. Hubbard R.C., et al. Neutrophil accumulation in the lung in α1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J. Clin. Invest. 1991, 88:891-897.
79. Tanabe N., et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 183:1653-1659.
80. Brebner J.A., Stockley R.A. Recent advances in α-1-antitrypsin deficiency-related lung disease. Expert Rev. Respir. Med. 2013, 7:213-230.
81. Elliott P.R., et al. Lung polymers in Z α1-antitrypsin deficiency-related emphysema. Am. J. Respir. Cell Mol. Biol. 1998, 18:670-674.
82. Cichy J., et al. Biosynthesis of α1-proteinase inhibitor by human lung-derived epithelial cells. J. Biol. Chem. 1997, 272:8250-8255.
83. Mahadeva R., et al. Polymers of Z α1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am. J. Pathol. 2005, 166:377-386.
84. Holme J., et al. Studies of gamma-glutamyl 1 transferase in α-1 antitrypsin deficiency. COPD 2010, 7:126-132.
85. Meisinger C., et al. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006, 189:297-302.
86. Morrison H.M., et al. Lung lavage fluid from patients with α 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin. Sci. (Lond.) 1987, 72:373-381.
87. Stolk J., et al. Short-term variability of biomarkers of proteinase activity in patients with emphysema associated with type Z α-1-antitrypsin deficiency. Respir. Res. 2005, 6:47.
88. Stone P.J., et al. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in α-1-antitrypsin-deficient humans. Respiration 1995, 62:76-79.
89. Stoller J.K. Elastin degradation products as biomarkers in α-1 antitrypsin deficiency: lastin' impact?. COPD 2013, 10:403-404.
90. Carter R.I., et al. The fibrinogen cleavage product Aa-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 2011, 66:686-691.
91. Kay M.A., et al. Expression of human α 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:89-93.
92. Jaffe H.A., et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat. Genet. 1992, 1:372-378.
93. Rosenfeld M.A., et al. Adenovirus-mediated transfer of a recombinant α 1-antitrypsin gene to the lung epithelium in vivo. Science 1991, 252:431-434.
94. Morral N., et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity. Hum. Gene Ther. 1998, 9:2709-2716.
95. Schiedner G., et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 1998, 18:180-183.
96. Kay M.A., et al. Therapeutic serum concentrations of human α-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995, 21:815-819.
97. Lu Y., et al. Therapeutic level of functional human α 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J. Gene Med. 2006, 8:730-735.
98. Song S., et al. Stable therapeutic serum levels of human α-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2001, 8:1299-1306.
99. Song S., et al. Sustained secretion of human α-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14384-14388.
100. Alino S.F., et al. Expression of human α1-antitrypsin in mouse after in vivo gene transfer to hepatocytes by small liposomes. Biochem. Biophys. Res. Commun. 1994, 204:1023-1030.
101. Canonico A.E., et al. Aerosol and intravenous transfection of human α1-antitrypsin gene to lungs of rabbits. Am. J. Respir. Cell Mol. Biol. 1994, 10:24-29.
102. Brantly M.L., et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 αl-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 2006, 17:1177-1186.
103. Brantly M.L., et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16363-16368.
104. Flotte T.R., et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum. Gene Ther. 2011, 22:1239-1247.
105. De B.P., et al. High levels of persistent expression of α1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol. Ther. 2006, 13:67-76.
106. McNab G.L., et al. Modification of gene expression and increase in α1-antitrypsin (α1-AT) secretion after homologous recombination in α1-AT-deficient monocytes. Hum. Gene Ther. 2007, 18:1171-1177.
107. McNab G.L., et al. A novel model and molecular therapy for Z α-1 antitrypsin deficiency. Mamm. Genome 2012, 23:241-249.
108. Mueller C., et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol. Ther. 2012, 20:590-600.
109. Li C., et al. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14258-14263.
110. Mueller C., Flotte T.G. Gene-based therapy for α-1 antitrypsin deficiency. COPD 2013, 10(Suppl. I):44-49.
111. Wilson A.A., et al. Sustained expression of α1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am. J. Respir. Cell Mol. Biol. 2008, 39:133-141.
112. Ghaedi M., et al. Establishment of lentiviral-vector-mediated model of human α-1 antitrypsin delivery into hepatocyte-like cells differentiated from mesenchymal stem cells. Tissue Cell 2010, 42:181-189.
113. Li H., et al. Adipose tissue-derived mesenchymal stem cell-based liver gene delivery. J. Hepatol. 2011, 54:930-938.
114. Li H., et al. Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of α1-antitrypsin. Mol. Ther. 2010, 18:1553-1558.
115. Yusa K., et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011, 478:391-394.
116. Hersh C.P., et al. Chronic obstructive pulmonary disease in α1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004, 59:843-849.
117. Piitulainen E., et al. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with α 1-antitrypsin deficiency (PiZZ). Thorax 1997, 52:244-248.
118. Rodriguez F., et al. Glutathione S-transferase P1 and lung function in patients with α1-antitrypsin deficiency and COPD. Chest 2005, 127:1537-1543.
119. Novoradovsky A. Endothelial nitric oxide synthase as a potential susceptibility gene in the pathogenesis of emphysema in α1-antitrypsin deficiency. Am. J. Respir. Cell Mol. Biol. 1999, 20:441-447.
120. Barros-Tizon J.C., et al. Reduction of severe exacerbations and hospitalization-derived costs in α-1-antitrypsin-deficient patients treated with α-1-antitrypsin augmentation therapy. Ther. Adv. Respir. Dis. 2012, 6:67-78.
121. Wencker M., et al. Long-term treatment of α1-antitrypsin deficiency-related pulmonary emphysema with human α1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-α1-AT-study group. Eur. Respir. J. 1998, 11:428-433.